Clovis Oncology (NASDAQ: CLVS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.430 | -0.440 | -0.0100 | ||||
REV | 36.970M | 34.247M | -2.723M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Clovis Oncology (NASDAQ: CLVS) through any online brokerage.
Other companies in Clovis Oncology’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Fortress Biotech (NASDAQ:FBIO), HOOKIPA Pharma (NASDAQ:HOOK), CytomX Therapeutics (NASDAQ:CTMX) and Adverum Biotechnologies (NASDAQ:ADVM).
The latest price target for Clovis Oncology (NASDAQ: CLVS) was reported by HC Wainwright & Co. on Friday, May 6, 2022. The analyst firm set a price target for 0.00 expecting CLVS to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Clovis Oncology (NASDAQ: CLVS) is $0.69 last updated May 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Clovis Oncology.
Clovis Oncology’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Clovis Oncology.
Clovis Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.